Cellebrite DI (NASDAQ:CLBT) PT Raised to $7.00

Cellebrite DI (NASDAQ:CLBT – Get Rating) had its price objective increased by stock analysts at Needham & Company LLC from $6.50 to $7.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s target price suggests a potential upside of 21.42% from the company’s current price.

Separately, TheStreet raised Cellebrite DI from a “d+” rating to a “c-” rating in a research report on Friday, February 3rd. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Cellebrite DI has a consensus rating of “Moderate Buy” and an average price target of $8.60.

Cellebrite DI Price Performance

Shares of CLBT stock opened at $5.77 on Tuesday. The stock has a market cap of $1.09 billion, a P/E ratio of 9.45, a price-to-earnings-growth ratio of 1.00 and a beta of 1.19. Cellebrite DI has a one year low of $3.80 and a one year high of $7.63. The stock has a fifty day moving average price of $5.33 and a 200 day moving average price of $4.77.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CLBT. Swiss National Bank raised its stake in Cellebrite DI by 7.6% during the first quarter. Swiss National Bank now owns 89,000 shares of the company’s stock worth $570,000 after acquiring an additional 6,300 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Cellebrite DI by 159.3% in the first quarter. JPMorgan Chase & Co. now owns 49,499 shares of the company’s stock valued at $317,000 after buying an additional 30,410 shares in the last quarter. Blair William & Co. IL increased its stake in shares of Cellebrite DI by 3,021.1% in the first quarter. Blair William & Co. IL now owns 523,978 shares of the company’s stock valued at $3,353,000 after buying an additional 507,190 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Cellebrite DI in the first quarter valued at $127,000. Finally, State Street Corp increased its stake in shares of Cellebrite DI by 20.3% in the first quarter. State Street Corp now owns 155,440 shares of the company’s stock valued at $995,000 after buying an additional 26,240 shares in the last quarter. 21.66% of the stock is currently owned by institutional investors and hedge funds.

Cellebrite DI Company Profile

(Get Rating)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations. Its DI platform allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation.